Abstract
Investigations into the association between diabetic nephropathy (DN) and MTHFR C677T gene polymorphism in several case–control studies has yielded contradictory results. To shed light on these inconclusive findings, a meta-analysis of all available studies relating the C677T polymorphism to the risk of developing DN was conducted. The PubMed database was searched, and case–control studies investigating the association between MTHFR C677T gene polymorphism and DN were included in the meta-analysis. The meta-analysis included 15 studies, of which 8 involved Caucasians and 5 East Asians; 11 studies involved subjects with type 2 diabetes and 4 with type 1 diabetes. The main analysis (all studies) revealed significant heterogeneity between the studies (P Q < 0.01) and a marginal association between the 677T allele and the risk of developing DN; the random effects (RE) pooled odds ratio (OR) was 1.30 (1.03–1.64). However, the sensitivity analysis (exclusion of studies not in Hardy–Weinberg equilibrium) produced non-significant results. The recessive model derived significant results in main analysis [fixed effects (FE) OR = 1.32 (1.10–1.58), P Q = 0.27], and in type 2 diabetes [FE OR = 1.30 (1.06–1.60), P Q = 0.38]. The additive model produced significant association in main analysis [RE OR = 1.65 (1.13–2.42), P Q < 0.01] in Caucasians [FE OR = 1.48 (1.11–1.98), P Q = 0.17] and in type 2 diabetes [RE OR = 1.65 (1.03–2.67), P Q < 0.01]. However, sensitivity analysis diminished the significant results in type 2 diabetes. There is no differential magnitude of effect in large versus small studies. In conclusion, although there is some evidence of association between MTHFR C677T gene polymorphism and DN, the above findings reinforce the need for further and more rigorous association studies.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101
Bluthner M, Bruntgens A, Schmidt S, Strojek K, Grzeszczak W, Ritz E (1999) Association of methylenetetrahydrofolate reductase gene polymorphism and diabetic nephropathy in type 2 diabetes? Nephrol Dial Transplant 14:56–57
Boger CA, Stubanus M, Haak T, Götz AK, Christ J, Hoffmann U, Riegger GA, Krämer BK (2007) Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end-stage diabetic nephropathy. Nephrol Dial Transplant 22:154–162
Borch-Johnsen K, Norgaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T, Parving HH (1992) Is diabetic nephropathy an inherited complication? Kidney Int 41:719–722
Bostom AG, Selhub J, Jacques PF, Rosenberg IH (2001) Power shortage: clinical trials testing the “homocysteine hypothesis” against a background of folic acid-fortified cereal grain flour. Ann Intern Med 135:133–137
Boushey CJ, Beresford SA, Omenn GS, Motulsky AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274:1049–1057
Buysschaert M, Gala JL, Bessomo A, Hermans MP (2004) C677T methylene-tetrahydrofolate reductase mutation in type 2 diabetic patients with and without hyperhomocysteinaemia. Diabetes Metab 30:349–354
Chico A, Perez A, Cordoba A, Arcelús R, Carreras G, de Leiva A, González-Sastre F, Blanco-Vaca F (1998) Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 41:684–693
Clayton D, McKeigue PM (2001) Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 358:1356–1360
Constans J, Blann AD, Resplandy F, Parrot F, Seigneur M, Renard M, Amiral J, Guérin V, Boisseau MR, Conri C (1999) Endothelial dysfunction during acute methionine load in hyperhomocysteinaemic patients. Atherosclerosis 147:411–413
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
Egger M, Davey SG, Schneider M, Minder C (1997a) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G (1997b) Language bias in randomised controlled trials published in English and German. Lancet 350:326–329
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111–113
Fujita H, Narita T, Meguro H, Ishii T, Hanyu O, Suzuki K, Kamoi K, Ito S (1999) No association between MTHFR gene polymorphism and diabetic nephropathy in Japanese type II diabetic patients with proliferative diabetic retinopathy. J Diabetes Complicat 13:284–287
Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, Rozen R (1994) Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet 7:195–200
Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T (2005) Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28:164–176
Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC (1998) Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima diabetes genes group. Diabetes 47:821–830
Ioannidis JP, Trikalinos TA, Zintzaras E (2006) Extreme between-study homogeneity in meta-analyses could offer useful insights. J Clin Epidemiol 59:1023–1032
Kang SS, Wong PW, Bock HG, Horwitz A, Grix A (1991) Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet 48:546–551
Ksiazek P, Bednarek-Skublewska A, Buraczynska M (2004) The C677T methylenetetrahydrofolate reductase gene mutation and nephropathy in type 2 diabetes mellitus. Med Sci Monit 10:BR47–BR51
Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC (1992) Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 327:248–254
Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R (1997) Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 57:1098–1102
Maeda M, Yamamoto I, Fujio Y, Azuma J (2003) Homocysteine induces vascular endothelial growth factor expression in differentiated THP-1 macrophages. Biochim Biophys Acta 1623:41–46
Makita Y, Moczulski DK, Bochenski J, Smiles AM, Warram JH, Krolewski AS (2003) Methylenetetrahydrofolate reductase gene polymorphism and susceptibility to diabetic nephropathy in type 1 diabetes. Am J Kidney Dis 41:1189–1194
McCully KS (1969) Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56:111–128
McCully KS (1996) Homocysteine and vascular disease. Nat Med 2:386–389
Moczulski D, Fojcik H, Zukowska-Szczechowska E, Szydlowska I, Grzeszczak W (2003) Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy. Nephrol Dial Transplant 18:1535–1540
Mtiraoui N, Ezzidi I, Chaieb M, Marmouche H, Aouni Z, Chaieb A, Mahjoub T, Vaxillaire M, Almawi WY (2007) MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Diabetes Res Clin Pract 75:99–106
Neugebauer S, Baba T, Watanabe T (1998) Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet 352:454
Odawara M, Yamashita K (1999): A common mutation of the methylenetetrahydrofolate reductase gene as a risk factor for diabetic nephropathy. Diabetologia 42:631–632
Passaro A, Calzoni F, Volpato S, Nora ED, Pareschi PL, Zamboni PF, Fellin R, Solini A (2003) Effect of metabolic control on homocysteine levels in type 2 diabetic patients: a 3-year follow-up. J Intern Med 254:264–271
Quinn M, Angelico MC, Warram JH, Krolewski AS (1996) Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39:940–945
Roybal CN, Yang S, Sun CW, Hurtado D, Vander Jagt DL, Townes TM, Abcouwer SF (2004) Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4. J Biol Chem 279:14844–14852
Shcherbak NS, Shutskaya ZV, Sheidina AM, Larionova VI, Schwartz EI (1999) Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in IDDM patients. Mol Genet Metab 68:375–378
Shpichinetsky V, Raz I, Friedlander Y, Goldschmidt N, Wexler ID, Ben-Yehuda A, Friedman G (2000) The association between two common mutations C677T and A1298C in human methylenetetrahydrofolate reductase gene and the risk for diabetic nephropathy in type II diabetic patients. J Nutr 130:2493–2497
Smyth JS, Savage DA, Maxwell AP (1999) MTHFR gene polymorphism and diabetic nephropathy in type 1 diabetes. Lancet 353:1156–1157
Strojek K, Grzeszczak W, Morawin E, Adamski M, Lacka B, Rudzki H, Schmidt S, Keller C, Ritz E (1997) Nephropathy of type II diabetes: evidence for hereditary factors? Kidney Int 51:1602–1607
Sun J, Xu Y, Zhu Y, Lu H (2004) Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Res Clin Pract 64:185–190
Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS, Chen S (2006) Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 17:3093–3104
Weir BS (1996) Genetic data analysis II: methods for discrete population genetic data. Sinauer, Sunderland
Whitehead A (2002) Meta-analysis of controlled clinical trials. Wiley, Chichester
Yoshioka K, Yoshida T, Umekawa T, Kogure A, Takakura Y, Toda H, Yoshikawa T (2004) Methylenetetrahydrofolate reductase gene polymorphism is not related to diabetic nephropathy in Japanese Type 2 diabetic patients. Diabet Med 21:1051–1052
Zintzaras E (2006a) Association of methylenetetrahydrofolate reductase (MTHFR) polymorphisms with genetic susceptibility to gastric cancer: a meta-analysis. J Hum Genet 51:618–624
Zintzaras E (2006b) Methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: a meta-analysis. Clin Genet 69:327–336
Zintzaras E (2006c) C677T and A1298C methylenetetrahydrofolate reductase gene polymorphisms in schizophrenia, bipolar disorder and depression: a meta-analysis of genetic association studies. Psychiatr Genet 16:105–115
Zintzaras E (2007) Brain-derived neurotrophic factor gene polymorphisms and schizophrenia: a meta-analysis. Psychiatr Genet 17:69–75
Zintzaras E, Hadjigeorgiou GM (2004) Association of paraoxonase 1 gene polymorphisms with risk of Parkinson’s disease: a meta-analysis. J Hum Genet 49:474–481
Zintzaras E, Hadjigeorgiou GM (2005) The role of G196A polymorphism in the brain-derived neurotrophic factor gene in the cause of Parkinson’s disease: a meta-analysis. J Hum Genet 50:560–566
Zintzaras E, Ioannidis JP (2005a) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28:123–137
Zintzaras E, Ioannidis JP (2005b) HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics 21:3672–3673
Zintzaras E, Kaditis AG (2007) Sleep-disordered breathing and blood pressure in children: a meta-analysis. Arch Pediatr Adolesc Med 161:172–178
Zintzaras E, Stefanidis I (2005) Association between the GLUT1 gene polymorphism and the risk of diabetic nephropathy: a meta-analysis. J Hum Genet 50:84–91
Zintzaras E, Chatzoulis DZ, Karabatsas CH, Stefanidis I (2005) The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis. J Hum Genet 50:267–275
Zintzaras E, Kitsios G, Stefanidis I (2006a) Endothelial NO synthase gene polymorphisms and hypertension: a meta-analysis. Hypertension 48:700–710
Zintzaras E, Rodopoulou P, Koukoulis GN (2006b) BsmI, TaqI, ApaI and FokI polymorphisms in the vitamin D receptor (VDR) gene and the risk of osteoporosis: a meta-analysis. Dis Markers 22:317–326
Zintzaras E, Koufakis T, Ziakas PD, Rodopoulou P, Giannouli S, Voulgarelis M (2006c) A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in acute lymphoblastic leukemia. Eur J Epidemiol 21:501–510
Zintzaras E, Stefanidis I, Santos M, Vidal F (2006d) Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? Hepatology 43:352–361
Acknowledgements
We thank Nikos Sdoukopoulos for assistance in data extraction and Mauro Santos for comments and discussion on genetic contrasts.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zintzaras, E., Uhlig, K., Koukoulis, G.N. et al. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy: a meta-analysis. J Hum Genet 52, 881–890 (2007). https://doi.org/10.1007/s10038-007-0189-3
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1007/s10038-007-0189-3
Keywords
This article is cited by
-
Interaction of MTHFR C677T polymorphism with smoking in susceptibility to diabetic nephropathy in Chinese men with type 2 diabetes
Journal of Human Genetics (2019)
-
Interaction of eNOS polymorphism with MTHFR variants increase the risk of diabetic nephropathy and its progression in type 2 diabetes mellitus patients
Molecular and Cellular Biochemistry (2011)
-
Trends in meta-analysis of genetic association studies
Journal of Human Genetics (2008)
-
The role of MTHFR gene in multiple myeloma
Journal of Human Genetics (2008)
-
Maternal gene polymorphisms involved in folate metabolism and risk of Down syndrome offspring: a meta-analysis
Journal of Human Genetics (2007)
